Surficial geologic map of the Des Moines Lobe of Iowa, Phase 5: Polk County

https://ir.uiowa.edu/igs_ofm/1030/thumbnail.jp

KEGG analysis of differentially methylated genes between the streptomycin-resistant and normal groups.

KEGG analysis of differentially methylated genes between the streptomycin-resistant and normal groups.</p

Transcriptome atlas and KEGG analysis of differentially expressed genes between the streptomycin-resistant and normal groups.

A) The heatmap was used to show the differentially expressed genes between the streptomycin-resistant and normal groups. B) KEGG analysis was used to compare the differentially expressed genes in the streptomycin-resistant and normal groups. Rich factor indicated the ratio of the number of differentially expressed genes enriched in each KEGG term to the number of all annotated genes in the KEGG term. Negative binomial distribution model was used to calculate P-value.</p

Differentially methylated genes between the streptomycin-resistant and normal groups.

Differentially methylated genes between the streptomycin-resistant and normal groups.</p

Association between DNMT3A Mutations and Prognosis of Adults with <i>De Novo</i> Acute Myeloid Leukemia: A Systematic Review and Meta-Analysis

<div><p>Background</p><p>DNA methyltransferase 3A (DNMT3A) mutations were considered to be independently associated with unfavorable prognosis in adults with de novo acute myeloid leukemia (AML), however, there are still debates on this topic. Here, we aim to further investigate the association between DNMT3A mutations and prognosis of patients with AML.</p> <p>Methods</p><p>Eligible studies were identified from several data bases including PubMed, Embase, Web of Science, ClinicalTrials and the Cochrane Library (up to June 2013). The primary endpoint was overall survival (OS), while relapse-free survival (RFS) and event-free survival (EFS) were chosen as secondary endpoints. If possible, we would pool estimate effects (hazard ratio [HR] with 95% confidence interval[CI]) of outcomes in random and fixed effects models respectively.</p> <p>Results</p><p>That twelve cohort studies with 6377 patients exploring the potential significance of DNMT3A mutations on prognosis were included. Patients with DNMT3A mutations had slightly shorter OS (HR = 1.60; 95% CI, 1.31–1.95; P<0.001), as compared to wild-type carriers. Among the patients younger than 60 years of age, DNMT3A mutations predicted a worse OS (HR = 1.84; 95% CI, 1.36–2.50; P<0.001). In addition, mutant DNMT3A predicted inferior OS (HR = 2.30; 95% CI, 1.78–2.97; P = 0.862) in patients with unfavorable genotype abnormalities. Similar results were also found in some other subgroups. However, no significant prognostic value was found on OS (HR = 1.40; 95% CI, 0.98–1.99; P = 0.798) in the favorable genotype subgroup. Similar results were found on RFS and EFS under different conditions.</p> <p>Conclusions</p><p>DNMT3A mutations have slightly but significantly poor prognostic impact on OS, RFS and EFS of adults with de novo AML in total population and some specific subgroups.</p> </div

Confunnel with filled studies from metatrim:

<p>mutant DNMT3A versus wild-type DNMT3A in a random effects model. The pooled HR on overall survival from 12 published studies is robust and the heterogeneity mainly results from unpublished studies.</p

Outcome of subgroups in a random effects model.

<p>N.of S., number of studies;</p><p>D+/−, indicates ratio of number of patients with mutant DNMT3A to patients with wild-type DNMT3A;</p><p>—, reflects there is no corresponding data presented; Abbreviations: mt, mutation; wt, wild type.</p

Forest plot of the HRs for relapse-free or event-free survival of AML patients.

<p>DNMT3A mutations versus wild-type DNMT3A. I–V Subtotal represented the pooled HRs with 95% CIs using a fixed effects model; D+L Subtotal represented the pooled HR with 95% CI using a random effects model.</p

PRISMA flow diagram for study review and inclusion.

<p>PRISMA flow diagram for study review and inclusion.</p

Multivariate analysis for relapse and OS in the allo-HSCT arm.

<p>Multivariate analysis for relapse and OS in the allo-HSCT arm.</p